The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
5
2
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
Role: collaborator
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
Role: collaborator
Cross-cultural Adaptation and Validation of the P-CIN for Chinese Pediatric Oncology Patients
Role: collaborator
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Role: collaborator
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
Role: collaborator
All 5 trials loaded